Citations

Clear

426 citation(s) found for "ST, Reza".

Developing an Echocardiography-Based, Automatic Deep Learning Framework for the Differentiation of Increased Left Ventricular Wall Thickness Etiologies
Banerjee, Imon , Jeong, Jiwoong , R, Amith Seri, Barry, Timothy , Neuman, Hana, Campany, Megan , Abdou, Merna , O'Shea, Michael P., Smith, Sean B. , Abraham, Bishoy , Hosseini, Seyedeh Maryam , Wang, Yuxiang , Lester, Steven J., Wilansky, Susan , Steidley, Eric, Rosenthal, Julie , Appleton, Christopher, Shen, Win‐Kuang , Grogan, Martha , Kane, G C, Oh, Jae K. , Patel, Bhavik N. , Banerjee, Imon , Li, James , Chao, Chieh‐Ju , O’Shea, Michael, Alsidawi, Said , Oh, Jae K. , Arsanjani, Reza

Mayo Clinic

No container title available | September 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166257188.84471102/v1 Get It

Aims Increased LV wall thickness is frequently encountered in transthoracic echocardiography (TTE). While accurate and early diagnosis is clinically important, given the differences in available therapeutic options and prognosis, an extensive workup is often required to establish the diagnosis. We propose the first echo-based, automated deep learning model with a fusion architecture to facilitate the evaluation and diagnosis of increased left ventricular (LV) wall thickness. Methods and Results Patients with an established diagnosis of increased LV wall thickness (hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HTN)/others) between 1/2015 to 11/2019 at Mayo Clinic Arizona were identified. The cohort was divided into 80%/10%/10% for training, validation, and testing sets, respectively. Six baseline TTE views were used to optimize a pre-trained InceptionResnetV2 model. Each model output was used to train a meta-learner under a fusion architecture. Model performance was assessed by multiclass area under the receiver operating characteristic curve (AUROC). A total of 586 patients were used for the final analysis (194 HCM, 201 CA, and 191 HTN/others). The mean age was 55.0 years, and 57.8% were male. Among the individual view-dependent models, the apical 4 chamber model had the best performance (AUROC: HCM: 0.94, CA: 0.73, and HTN/other: 0.87). The final fusion model outperformed all the view-dependent models (AUROC: CA: 0.90, HCM: 0.93, and HTN/other: 0.92). Conclusion The echo-based InceptionResnetV2 fusion model can accurately classify the main etiologies of increased LV wall thickness and can facilitate the process of diagnosis and workup.
Surgical Management of Aortic Regurgitation in Takayasu’s Arteritis: A Systematic Review of Techniques and Outcomes
Fath, Ayman R , Mookadam, Farouk, Aglan, Amro , Eldaly, Abdullah S. , Jahanyar, Jama , Shamoun, Fadi , Lee, Howard R., Solsi, Anup , Israr, Sharjeel, Mihyawi, Nawfal, Agasthi, Pradyumna , Mookadam, Farouk , Arsanjani, Reza

Mayo Clinic

The Permanente Journal | August 2, 2022 | Volume: 26 | Issue: 3 | Pages: 103-113

10.7812/tpp/21.017 | PMID 35939573 Get It

Racial disparities in inpatient clinical presentation, treatment, and outcomes in brain metastasis
McCray, Edwin , Waguia, Romaric, Price, Meghan , Williamson, Theresa , Dalton, Tara , Sciubba, Daniel M. , Yassari, Reza , Goodwin, Andrea N. , Fecci, Peter E. , Johnson, Margaret , Chaichana, Kaisorn L. , Dalton, Tara , Chaichana, Kaisorn, Fecci, Peter E , Ramos, Rafael De la Garza , Goodwin, C. Rory

Mayo Clinic

Neuro-Oncology Practice | July 31, 2022 | Volume: 10 | Issue: 1 | Pages: 62-70

10.1093/nop/npac061 | PMID 36659969 Get It

Abstract Background Few studies have assessed the impact of race on short-term patient outcomes in the brain metastasis population. The goal of this study is to evaluate the association of race with inpatient clinical presentation, treatment, in-hospital complications, and in-hospital mortality rates for patients with brain metastases (BM). Method Using data collected from the National Inpatient Sample between 2004 and 2014, we retrospectively identified adult patients with a primary diagnosis of BM. Outcomes included nonroutine discharge, prolonged length of stay (pLOS), in-hospital complications, and mortality. Results Minority (Black, Hispanic/other) patients were less likely to receive surgical intervention compared to White patients (odds ratio [OR] 0.70; 95% confidence interval [CI] 0.66–0.74, p < 0.001; OR 0.88; 95% CI 0.84–0.93, p < 0.001). Black patients were more likely to develop an in-hospital complication than White patients (OR 1.35, 95% CI 1.28–1.41, p < 0.001). Additionally, minority patients were more likely to experience pLOS than White patients (OR 1.48; 95% CI 1.41–1.57, p < 0.001; OR 1.34; 95% CI 1.27–1.42, p < 0.001). Black patients were more likely to experience a nonroutine discharge (OR 1.25; 95% CI 1.19–1.31, p < 0.001) and higher in-hospital mortality than White (OR 1.13; 95% CI 1.03–1.23, p = 0.008). Conclusion Our analysis demonstrated that race is associated with disparate short-term outcomes in patients with BM. More efforts are needed to address these disparities, provide equitable care, and allow for similar outcomes regardless of care.
Echocardiography in Cardiac Assist Devices
Anand, Senthil, Barry, Timothy, LeMond, Lisa , Arsanjani, Reza

Mayo Clinic

Reviews in Cardiovascular Medicine | July 19, 2022 | Volume: 23 | Issue: 7 | Pages: No page available

10.31083/j.rcm2307253 | PMID 39076924 Get It

In patients with medically refractory heart failure or cardiogenic shock, both temporary and durable mechanical circulatory support devices can be used to support cardiac circulation. Both transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) are widely available, relatively noninvasive, and avoid radiation exposure. Thus, echocardiography is an invaluable tool that provides vital information aiding in preprocedure evaluation, placement, management, and weaning of cardiac assist devices. The purpose of this article is to review the utility of both TTE and TEE in managing patients with cardiac assist devices.
Abstract LB568: Protein phosphatase 4 deficiency protects mice against cerulein-induced acute pancreatitis
Wang, Hua , Abbasgholizadeh, Reza , Moniruzzaman, Rohan , Ji, Baoan , Maitra, Anirban , Wang, Huamin

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: LB568-LB568

10.1158/1538-7445.am2022-lb568 Get It

Abstract Background: Pancreatitis is an inflammatory disease of the pancreas that causes significant morbidity and mortality and is one of the major risk factors for pancreatic cancer. Protein phosphatase 4 (PP4) has been reported to be overexpressed in breast, lung and pancreatic cancers. PP4 plays an important role in the regulation of centrosome maturation, DNA repair, NF-κB, and c-jun-NH2-kinase (JNK) signaling pathways. However, the expression and functions of PP4 in pancreatitis have not been studied. Methods: To examine the functions of PP4 in cerulein-induced acute pancreatitis (AP), we crossed PP4flox/+ mice with pancreatic acinar cell specific cre, CreERT, which was driven by a full length pancreatic acinar specific elastase I promoter. PP4flox/flox, CreERT mice and control mice were treated with 8 hourly intraperitoneal injections of cerulein (50 µg/kg/h). The pancreata were harvested at different time points for histopathological examination and molecular analysis. Results: PP4 expression was increased at both protein and mRNA levels in mouse pancreas with AP. Compared to CreERT mice, PP4flox/flox, CreERT mice demonstrated significantly less edema, less inflammation, less necrosis or loss of pancreatic acinar cells in pancreas after cerulein treatment. The serum amylase and lipase levels were lower in cerulein-treated PP4flox/flox, CreERT mice compared with controls. The pancreata of PP4flox/flox, CreERT mice exhibited decreased STAT3 Tyr705 phosphorylation and decreased NF-κB activation cerulein-treated PP4flox/flox, CreERT mice than control mice. Conclusion: Our findings demonstrated that PP4 plays an important role in cerulein-induced AP through STAT3 and NF-κB signaling pathways. Inhibition of PP4 may help to reduce the pancreatic injuries and to prevent the development of chronic pancreatitis, which increases the risk of pancreatic cancer. Citation Format: Hua Wang, Reza Abbasgholizadeh, Rohan Moniruzzaman, Baoan Ji, Anirban Maitra, Huamin Wang. Protein phosphatase 4 deficiency protects mice against cerulein-induced acute pancreatitis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB568.
Real-world genomic testing, treatment, and outcomes in patients with cholangiocarcinoma with FGFR2 fusions/rearrangements.
Conner, Therese , He, LiHong, Kazerooni, Reza, Salimi, Tehseen, Epstein, Robert S. , Borad, Mitesh J.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e16168-e16168

10.1200/jco.2022.40.16_suppl.e16168 Get It

e16168 Background: Several fibroblast growth factor receptor (FGFR) inhibitors have been recently approved or are in development for the treatment of cholangiocarcinoma (CCA) with FGFR2 fusions/rearrangements (f/r), such as the ATP-competitive inhibitors pemigatinib and infigratinib (FDA-approved in 2020/2021) and the covalent inhibitor futibatinib, which has shown efficacy in a pivotal phase 2 trial. To inform future evaluations of the impact of these agents in clinical practice, and understand other existing gaps in care, we investigated the characteristics and clinical management of patients with CCA and FGFR2 f/r prior to 2021. Methods: This real-world, retrospective cohort study used de-identified, patient-level electronic health records data from Cancer Treatment Centers of America (CTCA) to identify adults with a diagnosis of advanced intrahepatic CCA (iCCA) who received genomic testing between 2013-2021. Clinical/demographic characteristics, time to genomic testing, treatment patterns, and outcomes of patients with and without FGFR2 f/r were described. Results: 23 patients with FGFR2 f/r and 88 with FGFR wild-type (wt) iCCA were identified. Compared to FGFR wt, FGFR2 f/r had a higher proportion of female (65.2 vs 45.5%) and Black (39.1 vs 18.2%) patients (Table). Mean age at diagnosis was ̃60 y and >60% were diagnosed with stage 4 disease in both cohorts; 91.3% of f/r and 78.4% of wt patients had an ECOG PS 0/1. Median time from diagnosis to genomic testing was ̃5 mo; upon entry to CTCA, median time to testing was <2 mo. 17/23 patients in the f/r cohort had FGFR2 fusions (4 BICC1, 13 other). Three FGFR2 f/r patients received an FGFR inhibitor (pemigatinib) as next treatment after testing in 2020. A trend towards longer median overall survival in the f/r vs wt group (24.5 vs 17.8 mo), and a correlation of survival with ECOG PS were observed. Conclusions: This analysis provides insight into the real-world characteristics, clinical management and outcomes among patients with iCCA and FGFR2 f/r, predominantly prior to the introduction of FGFR inhibitors, providing a baseline for further study as the treatment landscape evolves. Of note, the time lag between diagnosis and genomic testing before entry to CTCA underlines the need for earlier testing to guide optimal therapy in clinical practice. [Table: see text]
The role of cytokines and their antagonists in the treatment of COVID‐19 patients
Afshar, Zeinab Mohseni , Barary, Mohammad , Pirzaman, Ali Tavakoli , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Ebrahimpour, Soheil , Mohseni Afshar, Zeinab , Babazadeh, Arefeh , Tavakoli Pirzaman, Ali , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Ebrahimpour, Soheil , Barary, Mohammad

Mayo Clinic

Reviews in Medical Virology | May 27, 2022 | Volume: 33 | Issue: 1 | Pages: No page available

10.1002/rmv.2372 | PMID 35621229 Get It

AbstractThe coronavirus disease 2019 (COVID‐19) has various presentations, of which immune dysregulation or the so‐called cytokine storm syndrome (COVID‐CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID‐19 infections, caused by the excessive release of pro‐inflammatory cytokines, such as interleukin‐1 (IL‐1), IL‐6, IL‐8, tumour necrosis factor, granulocyte‐macrophage colony‐stimulating factor, and interferon‐gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin‐6 receptor blocker approved to treat severe COVID‐19 infections.
Deep Neural Network for Cardiac Magnetic Resonance Image Segmentation
Chen, David , Bhopalwala, Huzefa , Dewaswala, Nakeya , Arunachalam, Shivaram P. , Enayati, Moein , Farahani, Nasibeh Zanjirani , Lokineni, Sravani, Bos, J. Martijn , Geske, Jeffrey B. , Ackerman, Michael J. , Araoz, Philip A. , Arruda‐Olson, Adelaide M. , Arunachalam, S P , Bos, Johan M , Geske, Jeffrey B , Pasupathy, Kalyan S. , Noseworthy, Peter A. , Arsanjani, Reza , Erickson, Bradley J.

Mayo Clinic

Journal of Imaging | May 23, 2022 | Volume: 8 | Issue: 5 | Pages: 149

10.3390/jimaging8050149 | PMID 35621913 Get It

The analysis and interpretation of cardiac magnetic resonance (CMR) images are often time-consuming. The automated segmentation of cardiac structures can reduce the time required for image analysis. Spatial similarities between different CMR image types were leveraged to jointly segment multiple sequences using a segmentation model termed a multi-image type UNet (MI-UNet). This model was developed from 72 exams (46% female, mean age 63 ± 11 years) performed on patients with hypertrophic cardiomyopathy. The MI-UNet for steady-state free precession (SSFP) images achieved a superior Dice similarity coefficient (DSC) of 0.92 ± 0.06 compared to 0.87 ± 0.08 for a single-image type UNet (p < 0.001). The MI-UNet for late gadolinium enhancement (LGE) images also had a superior DSC of 0.86 ± 0.11 compared to 0.78 ± 0.11 for a single-image type UNet (p = 0.001). The difference across image types was most evident for the left ventricular myocardium in SSFP images and for both the left ventricular cavity and the left ventricular myocardium in LGE images. For the right ventricle, there were no differences in DCS when comparing the MI-UNet with single-image type UNets. The joint segmentation of multiple image types increases segmentation accuracy for CMR images of the left ventricle compared to single-image models. In clinical practice, the MI-UNet model may expedite the analysis and interpretation of CMR images of multiple types.
A Comprehensive Review of PCSK9 Inhibitors
Coppinger, Caroline, Azemawah, Veronica, Hashemzadeh, Mehrnoosh , Hashemzadeh, Mehrnoosh , Movahed, Mohammad Reza , Peyton, Lee , Gregory, James

Mayo Clinic

Journal of Cardiovascular Pharmacology and Therapeutics | May 20, 2022 | Volume: 27 | Issue: No issue available | Pages: No page available

10.1177/10742484221100107 | PMID 35593194 Get It

Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) levels for which statins have been successful in reducing serum LDL-C to healthy concentrations. However, patients who are statin intolerant or those who do not achieve their treatment goals while on high-intensity statin therapy, such as those with familial hypercholesterolemia, remain at risk. With the discovery of PCSK9 inhibitors, the ability to provide more aggressive treatment for patients with homozygous and heterozygous familial hypercholesterolemia has increased. Ezetimibe reduces LDL-C by 15%-20% when combined with statin. 2 , 3 Protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been found to achieve profound reductions in LDL-C (54%-74%) when added to statins. They have shown dramatic effects at lowering major adverse cardiovascular events (MACE) in high-risk patients 4 with LDL-C levels ≥70 mg/dL and can be used in populations that are statin intolerant or not at goal levels with maximally tolerated statin therapy. PCSK9 inhibitors also produce minimal side effects. Myopathy, a common side effect for patients on statins, has been rare in patients on PCSK9 inhibitors. Randomized trials have shown that reduction in LDL-C has translated to clinical benefits even in patients who have not achieved their LDL-C target.